Upstate Active Clinical Trials
Study Title:EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
What is the purpose of the study?This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Upstate Institutional Review Board (IRB) Number:913688
Patient Age Group:Adults
Principal Investigator:Stephen L Graziano, MD
Where will the study take place?Upstate Cancer Center-All procedures
Who can I contact for more information?
Name: Eunice B Awuah, PhD